Company

Enable Biosciences (United States)

San Francisco, United States · enablebiosciences.com

Manage this page

Citations, last 5 years: 158
Works, last 5 years: 20
h-index: 31
Scientists listed: 3
Grants since 2016: 14

Grants received

2021–2022 · grant · Standard Grant

SBIR Phase I: Antibody-Enzyme Fusion for the Treatment of Myotubular Myopathy

Robert Shaffer · Enable Biosciences (United States) · funded by National Science Foundation

$251k

2021–2023 · research · R41

VAL-0914 Decreases PAO to Protect Against Cardiac Proteinopathies

Robert Shaffer · Enable Biosciences (United States) · funded by National Institutes of Health

$450k

2019–2021 · research · R44

Development of An Automated High-Throughput Dried Blood Spot Assay to Facilitate Large Scale Screening for Type 1 Diabetes Risk

David Seftel · Enable Biosciences (United States) · funded by National Institutes of Health

$746.6kBiosimilars and Bioanalytical Methods

2019–2022 · research · R44

Development of An Automated High-Throughput Dried Blood Spot Assay to Facilitate Large Scale Screening for Type 1 Diabetes Risk

David Seftel · Enable Biosciences (United States) · funded by National Institutes of Health

$741.2kBiosimilars and Bioanalytical Methods

2019–2021 · research · R43

Early and accurate differential diagnosis of Lyme and other tick-borne diseases by agglutination-PCR

David Seftel · Enable Biosciences (United States) · funded by National Institutes of Health

$225kVector-borne infectious diseases

2018–2023 · research · R44

Multiplex food allergy diagnostic based on IgE immunologic markers

David Seftel · Enable Biosciences (United States) · funded by National Institutes of Health

$644.6kFood Allergy and Anaphylaxis Research

2018–2020 · research · R43

Multiplex food allergy diagnostic based on IgE immunologic markers

David Seftel · Enable Biosciences (United States) · funded by National Institutes of Health

$223.8kFood Allergy and Anaphylaxis Research

2018–2022 · research · R44

Multiplex food allergy diagnostic based on IgE immunologic markers

David Seftel · Enable Biosciences (United States) · funded by National Institutes of Health

$845.8kFood Allergy and Anaphylaxis Research

2016–2026 · research · R44

Advancing an accessible, high-throughput and multiplex islet autoantibody test with self-collected capillary dried blood spots for regulatory clearance

David Seftel · Enable Biosciences (United States) · funded by National Institutes of Health

$968.5kDiabetes and associated disorders

2016–2026 · research · R44

Advancing an accessible, high-throughput and multiplex islet autoantibody test with self-collected capillary dried blood spots for regulatory clearance

David Seftel · Enable Biosciences (United States) · funded by National Institutes of Health

$990kDiabetes and associated disorders

2016–2020 · research · R44

An Ultrasensitive, High-Throughput, and Low-Cost Autoimmunity Panel for the Early Diagnosis and Improved Treatment of Type 1 Diabetes

David Seftel · Enable Biosciences (United States) · funded by National Institutes of Health

$749.8kDiabetes and associated disorders

2016–2017 · research · R43

Antibody-Detection-by-Agglutination-PCR (ADAP): An Ultra-Sensitive, High-Throughput, Multiplexable Tool for T1D Diagnosis and Monitoring

David Seftel · Enable Biosciences (United States) · funded by National Institutes of Health

$224.4kDiabetes and associated disorders

2016–2021 · research · R44

An Ultrasensitive, High-Throughput, and Low-Cost Autoimmunity Panel for the Early Diagnosis and Improved Treatment of Type 1 Diabetes

David Seftel · Enable Biosciences (United States) · funded by National Institutes of Health

$749.8kDiabetes and associated disorders

2016–2026 · research · R44

Advancing an accessible, high-throughput and multiplex islet autoantibody test with self-collected capillary dried blood spots for regulatory clearance

David Seftel · Enable Biosciences (United States) · funded by National Institutes of Health

$960.8k